SGO

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Retrieved on: 
Lunedì, Marzo 11, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, FAK, Patient, Research, RAMP, Cancer, SGO, Society, Woman, Clinical trial, Verastem Oncology, DRS, MEK, Gynecologic Oncology (journal), Consultant, Annual general meeting, Pharmaceutical industry

Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.

Key Points: 
  • Verastem will have an exhibition booth (#420) at the meeting to provide an overview of its ongoing cancer research.
  • “In addition, the plenary oral presentation highlighting preclinical efficacy of avutometinib in combination with a FAK inhibitor reinforces the potential of this combination in low-grade serous ovarian cancer regardless of KRAS status.
  • Banerjee and Grisham are paid consultants for Verastem Oncology.
  • The multinational survey is supported by Verastem Oncology.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Martedì, Marzo 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Retrieved on: 
Domenica, Marzo 17, 2024
TSC1, Ovarian cancer, AADI, Endometrial cancer, Perivascular epithelioid cell tumour, EEC, Cervical cancer, Patient, Neoplasm, Cancer, Trial of the century, University, SGO, MD, Malignancy, Society, Safety, Gynecologic Oncology (journal), TSC2, FDA, Glomus tumor, Aadi, Pharmaceutical industry

LOS ANGELES, March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status. This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.

Key Points: 
  • The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status.
  • This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.
  • "Overactivation of the mTOR pathway has been implicated in gynecological cancers," said Loretta Itri, MD, Chief Medical Officer at Aadi.
  • "nab-Sirolimus is a nanoparticle albumin-bound (nab) mTOR inhibitor under investigation in TSC1- and TSC2-mutated tumors as well as other mTOR-driven tumors.

The Foundation for Women's Cancer is Calling on Everyone Connected to Women's Health to Move Today for More Tomorrows

Retrieved on: 
Sabato, Marzo 16, 2024
Ovarian cancer, Friends, Ginger, Organization, Assistant, Education, Social media, Research, SGO, FWC, Society, Woman, Cancer, Gynecologic Oncology (journal), Platinum, Movement, Pharmaceutical industry

CHICAGO, March 16, 2024 /PRNewswire-PRWeb/ -- The Foundation for Women's Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), is excited to announce the commencement of Move4Her 2024! Move4Her is the FWC's signature fundraising campaign that helps power research, education, and awareness of the five gynecologic (gyn) cancers. As part of Move4Her, individuals and teams are asked to commit five minutes or more each day to movement and encourage their friends and loved ones to support them on their Move4Her journey. Individuals and teams choose the activity or adventure of their choice to drive their movement, and will receive Move4Her resources to help spread awareness of their Move4Her commitment. In its fifth consecutive year, Move4Her is challenging participants to raise more awareness and accelerate the momentum towards a common goal – ending the five gyn cancers – cervical, ovarian, uterine/endometrial, vaginal and vulvar cancer.

Key Points: 
  • Move4Her is the FWC's signature fundraising campaign that helps power research, education, and awareness of the five gynecologic (gyn) cancers.
  • Ultimately, Move4Her participants fund life-changing programs that support better outcomes – more tomorrows now and for future generations, through donations and fundraising efforts.
  • "It is an absolute honor to be supported by the Move4Her participants and the Foundation for Women's Cancer.
  • Follow the FWC on its social media platforms Twitter , Instagram and Facebook for exciting updates throughout the year.

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Mercoledì, Marzo 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

You're Invited to Join Sonoro Gold Corp at PDAC 2024 Convention in Toronto

Retrieved on: 
Giovedì, Febbraio 29, 2024
Prospectors, Booth, MTCC, PDAC, SGO, Metro Toronto Convention Centre

Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Visit Sonoro Gold Corp (TSXV: SGO) (OTCQB: SMOFF) at Booth #3230 at the Prospectors & Developers Association of Canada’s (PDAC) Convention at the Metro Toronto Convention Centre (MTCC) from Sunday, March 3 to Wednesday, March 6, 2024.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Visit Sonoro Gold Corp (TSXV: SGO) (OTCQB: SMOFF) at Booth #3230 at the Prospectors & Developers Association of Canada’s (PDAC) Convention at the Metro Toronto Convention Centre (MTCC) from Sunday, March 3 to Wednesday, March 6, 2024.

Sonoro Gold Corp: Invitation to Red Cloud's Pre-PDAC 2024 Mining Showcase

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Cloud, Sheraton Centre Toronto Hotel, SGO

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Sonoro Gold Corp (TSXV: SGO) (OTCQB: SMOFF) is pleased to announce that the company will be presenting at Red Cloud's Pre-PDAC 2024 Mining Showcase.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Sonoro Gold Corp (TSXV: SGO) (OTCQB: SMOFF) is pleased to announce that the company will be presenting at Red Cloud's Pre-PDAC 2024 Mining Showcase.
  • We invite our shareholders and all interested parties to join us.
  • The annual conference will take place in-person at the Sheraton Centre Toronto Hotel February 29-March 1, 2024.
  • Kenneth MacLeod, President & CEO, will be presenting on February 29th at 11:20 a.m. Eastern Standard time.

SONORO GOLD ANNOUNCES CLOSING OF FIRST TRANCHE OF $1 MILLION NON-BROKERED PRIVATE PLACEMENT

Retrieved on: 
Martedì, Febbraio 20, 2024
TSX Venture Exchange, Multilateral, SGO, Policy, Minority, Offering

Each Unit consists of one Sonoro common share and one common share purchase warrant.

Key Points: 
  • Each Unit consists of one Sonoro common share and one common share purchase warrant.
  • Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of three years from the closing of the private placement at an exercise price of C$0.07 per share.
  • The net proceeds from the Offering will be used to fund the ongoing development of the Company’s Cerro Caliche gold project in Sonora, Mexico.
  • In connection with the First Tranche, the Company paid $3,500.00 in Finder’s fees and issued 70,000 in non-transferable Finder’s Warrants.

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Retrieved on: 
Mercoledì, Marzo 6, 2024
Biotechnology, Other Health, Health, General Health, Women, Pharmaceutical, Oncology, Research, Consumer, Science, Clinical Trials, Progression-free survival, Fudan University, Shanghai Cancer Center, ISD, PARP, ESGO, BRCA, HKEX, Platelet, OS, Gynecologic Oncology (journal), Ovarian cancer, SGO, Patient, Congress, Development, Niraparib, Pharmaceutical industry

“Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.

Key Points: 
  • “Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized starting dose among Chinese patients with PSROC,” said Dr. Rafael Amado, President, Head of Global Oncology Research and Development, Zai Lab.
  • “We look forward to sharing the final OS findings from this study at both the 2024 ESGO and SGO conferences.
  • The final OS analysis was conducted after ≥ 50% of OS events occurred in the intent-to-treat population.
  • No new safety signals were identified during the long-term follow up period subsequent to the primary analysis.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Martedì, Febbraio 20, 2024
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, MSD, Carboplatin, MRK, Society of Gynecologic Oncology, Food, PDUFA, Risk, Cancer, Gynecologic Oncology (journal), Death, Paclitaxel, SGO, Patient, Pharmaceutical industry

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 21, 2024.
  • The sBLA is based on data from the Phase 3 NRG-GY018 trial.
  • Health authorities in Israel, Canada, Australia, Singapore and Brazil will review this application as part of Project Orbis.
  • In endometrial cancer, Merck is evaluating KEYTRUDA in the first-line setting for advanced or recurrent disease that is dMMR (KEYNOTE-C93/ENGOT-en15/GOG-3064) and in the adjuvant setting (KEYNOTE-B21/ENGOT-en11/GOG-3053).